Pfizer conducted the AcroVoice study between November 2017 and July 2018 to understand how patients with acromegaly defined disease activity and treatment success.

Advocacy and support groups, including APPS, helped find patient volunteers to participate in the study. 100 patients with acromegaly in the United States and Canada took part.

In telephone interviews, patients identified five factors they considered to be important in describing disease activity:

• ·       Two clinical factors: the size of the pituitary tumor, and the levels of a hormone called insulin-like growth factor I (IGF-I for short), which can be elevated in patients with acromegaly.
• ·       Three patient-centered factors: related health conditions, symptoms, and quality of life.

A similar study, called ACRODAT, was carried out with doctors who treat acromegaly.

Find the full article—access is free—here: https://link.springer.com/article/10.1007%2Fs11102-018-00933-9